Trials / Active Not Recruiting
Active Not RecruitingNCT06545916
Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder
A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Consumption in Subjects Diagnosed With Moderate to Severe Alcohol Use Disorder and Seeking Treatment
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Imbrium Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunobinop | 1 tablet taken orally at bedtime |
| DRUG | Placebo to match sunobinop | 1 tablet taken orally at bedtime |
Timeline
- Start date
- 2024-10-14
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2024-08-09
- Last updated
- 2026-03-05
Locations
7 sites across 2 countries: United States, Romania
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06545916. Inclusion in this directory is not an endorsement.